# Orexo US Inc.

Canonical: https://abierto.us/vendors/orexo-us-inc-mn1mpmbcvvd5

- UEI: MN1MPMBCVVD5
- CAGE: 6Y7L3
- Parent: Orexo Ab
- Location: Morristown, NJ
- Awards in window: 3 (11 transactions), $11,450,712 obligated, January 29, 2024 to September 4, 2026

## Awarding agencies

- Office of Assistant Secretary for Preparedness and Response: 1 awards, $11,450,712
- Department of Veterans Affairs: 2 awards, $0

## Industries

- 541714 Research and Development in Biotechnology (except Nanobiotechnology): $11,450,712
- 325412 Pharmaceutical Preparation Manufacturing: $0
- 334510 Electromedical and Electrotherapeutic Apparatus Manufacturing: $0

## Competition

- Full and Open Competition: 3 awards

## Largest awards

- 75A50125C00010 (definitive contract): $11,450,712, Barda - Aspr / Daappo / Barda DCMA. Clinical Development of OX390 (Atipamezole) as an ?2 Agonist Reversal Agent for Human Use to Counteract the Sedative Effects of Xylazine, Medetomidine, and Other ?2 Agonists. https://www.usaspending.gov/award/CONT_AWD_75A50125C00010_7505_-NONE-_-NONE-/
- 36F79722D0163: $0, Nac Federal Supply Schedule. Cancellation. https://www.usaspending.gov/award/CONT_IDV_36F79722D0163_3600/
- V797D60656: $0, Nac Federal Supply Schedule. 2025 Public Law Pricing Update. https://www.usaspending.gov/award/CONT_IDV_V797D60656_3600/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/orexo-us-inc-mn1mpmbcvvd5.